- ICH GCP
- US-Register für klinische Studien
- Klinische Studie NCT00867087
Study Evaluating Inotuzumab Ozogamicin (CMC-544) Plus Rituximab In Diffuse Large B-Cell Non-Hodgkin's Lymphoma
30. Oktober 2017 aktualisiert von: Pfizer
An Open-label, Single-arm, Phase 2 Study Of Inotuzumab Ozogamicin Plus Rituximab In Subjects With Relapsed/Refractory Cd22-positive Diffuse Large B-cell Lymphoma, Eligible For Autologous Stem Cell Transplantation
The purpose of this study is to evaluate inotuzumab ozogamicin in combination with rituximab prior to an autologous stem cell transplant (aSCT) in patients with relapsed/refractory diffuse large B-cell Non-Hodgkin's lymphoma.
Studienübersicht
Status
Abgeschlossen
Bedingungen
Intervention / Behandlung
Studientyp
Interventionell
Einschreibung (Tatsächlich)
64
Phase
- Phase 2
Kontakte und Standorte
Dieser Abschnitt enthält die Kontaktdaten derjenigen, die die Studie durchführen, und Informationen darüber, wo diese Studie durchgeführt wird.
Studienorte
-
-
-
Berlin, Deutschland, 13353
- Charite Campus Virchow-Kilinikum-
-
-
-
-
-
Lille, Frankreich, 59037
- CHRU de Lille Hopital Claude Huriez
-
Marseille, Frankreich, 13273
- Institut Paoli Calmettes
-
Montpellier Cedex 5, Frankreich, 34295
- CHU Saint-Eloi
-
Paris, Frankreich, 75010
- Hopital Saint Louis
-
Pessac, Frankreich, 33604
- Hôpital Haut-Lévêque
-
Pierre-Benite cedex 114, Frankreich, 69495
- CH Lyon sud
-
Pierre-benite Cedex, Frankreich, 69495
- CH Lyon sud
-
Strasbourg, Frankreich, 67098
- Departement d'Hematologie et d'Oncologie-
-
-
-
-
-
Seoul, Korea, Republik von, 120-752
- Severance Hospital, Yonsei University Health System
-
-
Gangnam-gu
-
Seoul, Gangnam-gu, Korea, Republik von, 135-710
- Samsung Medical Center
-
-
Seoul/korea
-
Seoul, Seoul/korea, Korea, Republik von, 138-736
- Asan Medical Center
-
-
-
-
-
Singapore, Singapur, 169608
- Singapore General Hospital
-
-
-
-
Illinois
-
Maywood, Illinois, Vereinigte Staaten, 60153
- Loyola University Medical Center, Foster G. McGraw Hospital and Satellites
-
-
Massachusetts
-
Boston, Massachusetts, Vereinigte Staaten, 02111
- Tufts Medical Center
-
-
Michigan
-
Ann Arbor, Michigan, Vereinigte Staaten, 48109
- University Of Michigan Comprehensive Cancer Center
-
-
Missouri
-
Saint Louis, Missouri, Vereinigte Staaten, 63110
- Washington University School of Medicine
-
Saint Louis, Missouri, Vereinigte Staaten, 63110-1094
- Barnes-Jewish Hospital
-
Saint Peters, Missouri, Vereinigte Staaten, 63376
- Siteman Cancer Center
-
-
New Jersey
-
Hackensack, New Jersey, Vereinigte Staaten, 07601
- Hackensack University Medical Center
-
Hackensack, New Jersey, Vereinigte Staaten, 07601
- John Theurer Cancer Center, Hackensack University Medical Center
-
Hackensack, New Jersey, Vereinigte Staaten, 07601-1941
- John Theurer Cancer Center (JTCC) at Hackensack University Medical Center (HUMC)
-
Hackensack, New Jersey, Vereinigte Staaten, 07601-2105
- John Theurer Cancer Center (JTCC) at Hackensack University Medical Center (HUMC)
-
Hackensack, New Jersey, Vereinigte Staaten, 07601
- John Theurer Cancer Center (JTCC) at Hackensack University Medical Center (HUMC)
-
-
New York
-
New York, New York, Vereinigte Staaten, 10065
- Memorial Sloan - Kettering Cancer Center
-
-
Pennsylvania
-
Hershey, Pennsylvania, Vereinigte Staaten, 17033-0850
- Penn State Milton S Hershey Medical Center
-
-
Texas
-
Dallas, Texas, Vereinigte Staaten, 75390
- UT Southwestern Medical Center
-
Dallas, Texas, Vereinigte Staaten, 75235
- Zale Lipshy University Hospital
-
Dallas, Texas, Vereinigte Staaten, 75235
- UT Southwestern University Hospital - St. Paul
-
Houston, Texas, Vereinigte Staaten, 77030
- University of Texas, MD Anderson Cancer Center
-
Houston, Texas, Vereinigte Staaten, 77030-4009
- The University of Texas, M. D. Anderson Cancer Center
-
San Antonio, Texas, Vereinigte Staaten, 78229
- Methodist Healthcare System of
-
-
Wisconsin
-
Madison, Wisconsin, Vereinigte Staaten, 53792-0001
- University of Wisconsin Hospital and Clinics
-
Madison, Wisconsin, Vereinigte Staaten, 53792
- Pharmaceutical Research Center
-
-
-
-
-
Manchester, Vereinigtes Königreich, M20 4BX
- The Christie NHS Foundation Trust
-
Manchester, Vereinigtes Königreich, M20 4BX
- Christie Hospital
-
-
Teilnahmekriterien
Forscher suchen nach Personen, die einer bestimmten Beschreibung entsprechen, die als Auswahlkriterien bezeichnet werden. Einige Beispiele für diese Kriterien sind der allgemeine Gesundheitszustand einer Person oder frühere Behandlungen.
Zulassungskriterien
Studienberechtigtes Alter
18 Jahre und älter (Erwachsene, Älterer Erwachsener)
Akzeptiert gesunde Freiwillige
Nein
Studienberechtigte Geschlechter
Alle
Beschreibung
Inclusion Criteria:
- CD20/CD22-positive diffuse large B-cell NHL that has relapsed after 1 or 2 prior therapies; one prior therapy must include anthracyclines and one must include rituximab in combination with chemotherapy
- Relapsed/disease progression within 12 months after start of prior therapy and/or secondary International Prognostic Index (sIPI) score greater than 1
- Eligible for autologous stem cell transplant (aSCT)
Exclusion Criteria:
- Prior allogeneic hematopoietic stem cell transplant
- Within 6 months prior to test article: autologous transplant, treatment with anti-CD22 antibodies, radio-immunotherapy
- Veno-occlusive disease or sinusoidal obstruction syndrome, chronic liver disease, systemic vasculitides, current or chronic hepatitis B or C infection
Studienplan
Dieser Abschnitt enthält Einzelheiten zum Studienplan, einschließlich des Studiendesigns und der Messung der Studieninhalte.
Wie ist die Studie aufgebaut?
Designdetails
- Hauptzweck: Behandlung
- Zuteilung: Nicht randomisiert
- Maskierung: Keine (Offenes Etikett)
Waffen und Interventionen
Teilnehmergruppe / Arm |
Intervention / Behandlung |
|---|---|
|
Experimental: Rituximab 375 mg/m^2 + Inotuzumab Ozogamicin 1.8 mg/m^2
Inotuzumab ozogamicin, in combination with rituximab, will be administered to patients with relapsed/refractory diffuse large B-cell Non-Hodgkin's lymphoma prior to an autologous stem cell transplant (aSCT).
|
1.8 mg/m^2 every 21 days by intravenous infusion, 3 to 6 doses
Andere Namen:
375 mg/m^2 two days before cycle 1 by intravenous infusion; 375 mg/m^2 every 21 days by intravenous infusion, 3 to 6 doses
|
Was misst die Studie?
Primäre Ergebnismessungen
Ergebnis Maßnahme |
Maßnahmenbeschreibung |
Zeitfenster |
|---|---|---|
|
Percentage of Participants Achieving Complete Response (CR) or Partial Response (PR) After 3 Cycles of Inotuzumab Ozogamicin Plus Rituximab Therapy
Zeitfenster: Up to 2 years (9 weeks of 3 21-day cycles and every 3 to 6 months during the long-term follow-up period)
|
Response criteria based on National Cancer Institute (NCI) International Response Criteria for non-Hodgkin's lymphoma.
CR: no detectable clinical & radiographic evidence of disease/disease-related symptoms; lymph nodes/nodal masses regressed to normal size (less than or equal to [≤] 1.5 cm in greatest transverse diameter for nodes greater than [>] 1.5 cm pre-therapy); spleen & other organs (if enlarged pre-therapy) regressed in size & spleen not palpable on physical examination; repeat bone marrow infiltrate clear.
PR: > or equal to (≥) 50% decrease in sum of product diameters (SPD) of 6 largest dominant nodes/nodal masses; no increase in size of other nodes, liver, or spleen; splenic & hepatic nodules regressed by ≥ 50% in SPD; involvement of other organs usually assessable & no measurable disease present; no new sites of disease.
Participants achieving CR, but with persistent morphologic bone marrow involvement or no bone marrow assessment after treatment were partial responders.
|
Up to 2 years (9 weeks of 3 21-day cycles and every 3 to 6 months during the long-term follow-up period)
|
Sekundäre Ergebnismessungen
Ergebnis Maßnahme |
Maßnahmenbeschreibung |
Zeitfenster |
|---|---|---|
|
Kaplan-Meier Estimate of Progression Free Survival (PFS) 6 Months After Inotuzumab Ozogamicin Plus Rituximab Therapy
Zeitfenster: 6 months after the first dose of inotuzumab ozogamicin
|
PFS; time from date of randomization to earliest date of progression, relapse after CR, death from any cause without progression, start of new treatment for the lymphoma excluding treatments/procedures for consolidation therapy in this protocol, or censored at date of last tumor assessment.
Progression: abnormal lymph nodes (long axis > 1.5 cm or long axis 1.1 to 1.5 cm and short axis > 1.0 cm); appearance of any new lesion > 1.5 cm in any axis during or at end of treatment; ≥ 50% increase from nadir in SPD of any previously involved nodes, in a single involved node, or in the size of other lesions; ≥ 50% increase in longest diameter of any single previously identified node > 1.0 cm in short axis.
|
6 months after the first dose of inotuzumab ozogamicin
|
|
Kaplan-Meier Estimate of PFS 2 Years After Inotuzumab Ozogamicin Plus Rituximab Therapy
Zeitfenster: 2 years after the first dose of inotuzumab ozogamicin
|
PFS; time from date of randomization to earliest date of progression, relapse after CR, death from any cause without progression, start of new treatment for the lymphoma excluding treatments/procedures for consolidation therapy in this protocol, or censored at date of last tumor assessment.
Progression: abnormal lymph nodes (long axis > 1.5 cm or long axis 1.1 to 1.5 cm and short axis > 1.0 cm); appearance of any new lesion > 1.5 cm in any axis during or at end of treatment; ≥ 50% increase from nadir in SPD of any previously involved nodes, in a single involved node, or in the size of other lesions; ≥ 50% increase in longest diameter of any single previously identified node > 1.0 cm in short axis.
|
2 years after the first dose of inotuzumab ozogamicin
|
|
Percentage of Participants With a Response of CR or PR and Who Had Successful Granulocyte Colony Stimulating Factor (G-CSF) Mobilization of Peripheral Blood Stem Cells (PBSCs) Overall and After 3 Cycles of Inotuzumab Ozogamicin Plus Rituximab Therapy
Zeitfenster: From the first dose to approximately 2 to 3 weeks after 3 cycles of inotuzumab ozogamicin plus rituximab (induction) therapy (up to 12 weeks) and up to approximately 2 to 3 weeks after 6 cycles (up to 21 weeks).
|
Successful mobilization of PBSC: ≥ 2 x 10^6 cluster of differentiation (CD) 34+ cells per kilogram (cells/kg) after 3 cycles.
CR: no detectable clinical & radiographic evidence of disease/disease-related symptoms; lymph nodes/nodal masses regressed to normal size (≤ 1.5 cm in greatest transverse diameter for nodes > 1.5 cm pre-therapy); spleen & other organs (if enlarged pre-therapy) regressed in size & spleen not palpable on physical examination; repeat bone marrow infiltrate clear.
PR: ≥ 50% decrease in SPD of 6 largest dominant nodes/nodal masses; no increase in size of other nodes, liver, or spleen; splenic & hepatic nodules regressed by ≥ 50% in SPD; involvement of other organs usually assessable & no measurable disease present; no new sites of disease.
Participants achieving CR, but with persistent morphologic bone marrow involvement or no bone marrow assessment post treatment were partial responders.
Response includes confirmed CR/PR and unconfirmed CR/PR.
|
From the first dose to approximately 2 to 3 weeks after 3 cycles of inotuzumab ozogamicin plus rituximab (induction) therapy (up to 12 weeks) and up to approximately 2 to 3 weeks after 6 cycles (up to 21 weeks).
|
|
Percentage of Participants With Successful G-CSF Mobilization of PBSC
Zeitfenster: From the first dose to approximately 2 to 3 weeks after up to 6 cycles of inotuzumab ozogamicin plus rituximab (induction) therapy (up to 21 weeks).
|
Successful mobilization of PBSC was defined as ≥ 2 x 10^6 CD34+ cells/kg collected after 3 cycles of inotuzumab ozogamicin plus rituximab therapy.
|
From the first dose to approximately 2 to 3 weeks after up to 6 cycles of inotuzumab ozogamicin plus rituximab (induction) therapy (up to 21 weeks).
|
|
Percentage of Participants Who Underwent Autologous Stem Cell Transplant (aSCT)
Zeitfenster: A minimum of 4 weeks and a maximum of 8 weeks after the last cycle of inotuzumab ozogamicin plus rituximab (induction) therapy (up to 26 weeks).
|
Participants underwent high dose chemotherapy and aSCT.
In order to proceed to aSCT, participants were required to achieve CR or PR and successful collection of PSBC (≥ 2.0 x 10^6 CD34+ cells/kg collected after 3 cycles).
|
A minimum of 4 weeks and a maximum of 8 weeks after the last cycle of inotuzumab ozogamicin plus rituximab (induction) therapy (up to 26 weeks).
|
|
Event-Free Survival (EFS) After aSCT
Zeitfenster: From the completion of aSCT through 2 year long-term follow-up period, including but not limited to planned assessments scheduled every 3 to 6 months.
|
EFS was the time (in months) from the date of aSCT to the earliest date of progression, relapse after CR, death from any cause without progression, initiation of a new treatment for the lymphoma or was censored at the date of the last tumor assessment.
|
From the completion of aSCT through 2 year long-term follow-up period, including but not limited to planned assessments scheduled every 3 to 6 months.
|
|
Percentage of Participants With a CR After 3 Cycles of Inotuzumab Ozogamicin Plus Rituximab Therapy
Zeitfenster: From the first dose to approximately 2 to 3 weeks after 3 cycles of inotuzumab ozogamicin plus rituximab (induction) therapy (up to 12 weeks).
|
CR: complete disappearance of all detectable clinical & radiographic evidence of disease & disease-related symptoms; lymph nodes & nodal masses regressed to normal size (≤ 1.5 cm in their greatest transverse diameter for nodes > 1.5 cm before therapy); spleen and other organs (if enlarged prior to therapy) regressed in size & spleen not palpable on physical examination; repeat bone marrow infiltrate clear.
Response includes confirmed CR and unconfirmed CR.
|
From the first dose to approximately 2 to 3 weeks after 3 cycles of inotuzumab ozogamicin plus rituximab (induction) therapy (up to 12 weeks).
|
|
Overall Survival (OS)
Zeitfenster: From randomization until the date of death, or the date of last contact if no death occurred (up to 2 years).
|
OS was the time (in months) from the date of randomization to the date of death, and censored at the date of last contact if no death occurred.
|
From randomization until the date of death, or the date of last contact if no death occurred (up to 2 years).
|
|
Percentage of Participants With Any Grade 3/4 Laboratory Abnormality During Therapy
Zeitfenster: Within 3 days prior each dose of test article, on Day -2, 1, 8, and 15 of Cycles 1 to 3, 2 to 3 weeks after Cycle 3, at the end-of-treatment visit, and every 3 to 6 months during long-term follow-up (up to 2 years).
|
The following parameters were analyzed for serum chemistry; blood urea nitrogen (or urea), creatinine, glucose, calcium, sodium, potassium, phosphorus, lactate dehydrogenase, aspartate aminotransferase, alanine aminotransferase, total bilirubin (and direct bilirubin, if total bilirubin was elevated), alkaline phosphatase, uric acid (or urate), albumin and total protein.
The following parameters were analyzed for hematology; lymphocytes, basophils, eosinophils, erythrocytes, hematocrit, hemoglobin, leukocytes, monocytes, neutrophils, platelets, prothrombin international normalized ratio, prothrombin time, fibrinogen, and activated partial thromboplastin time.
Laboratory test results were graded using the NCI Common Terminology Criteria for Adverse Events, version 3.0 (CTCAE v3.0).
|
Within 3 days prior each dose of test article, on Day -2, 1, 8, and 15 of Cycles 1 to 3, 2 to 3 weeks after Cycle 3, at the end-of-treatment visit, and every 3 to 6 months during long-term follow-up (up to 2 years).
|
|
Percentage of Participants With Treatment-Emergent Adverse Events (AEs) During Inotuzumab Ozogamicin Plus Rituximab Treatment
Zeitfenster: Treatment emergent AEs were collected from time of first dose to end of trial visit (participants not undergoing consolidation treatment) or until consolidation therapy. SAEs were collected from informed consent until end of trial visit (up to 6 months).
|
An AE was any untoward, undesired, or unplanned event in the form of signs, symptoms, disease, or laboratory/physiologic observations occurring in a participant given a test article or in a clinical study; the event may not necessarily have had a causal relationship with the treatment.
A serious adverse event (SAE) was an AE resulting in any of the following outcomes or deemed significant for any other reason: death; initial or prolonged in-patient hospitalization; life-threatening experience (immediate risk of dying); persistent or significant disability/incapacity; congenital anomaly; cancer.
Treatment-emergent AEs were AEs that emerged after the first dose of the study treatment during the treatment period that were absent pre-treatment, or worsened during the treatment period relative to the pre-treatment state.
The severity of all AEs was graded by the investigator using the NCI Common Terminology Criteria for AE Version 3.0 (CTCAE v3.0).
|
Treatment emergent AEs were collected from time of first dose to end of trial visit (participants not undergoing consolidation treatment) or until consolidation therapy. SAEs were collected from informed consent until end of trial visit (up to 6 months).
|
Mitarbeiter und Ermittler
Hier finden Sie Personen und Organisationen, die an dieser Studie beteiligt sind.
Sponsor
Mitarbeiter
Publikationen und hilfreiche Links
Die Bereitstellung dieser Publikationen erfolgt freiwillig durch die für die Eingabe von Informationen über die Studie verantwortliche Person. Diese können sich auf alles beziehen, was mit dem Studium zu tun hat.
Studienaufzeichnungsdaten
Diese Daten verfolgen den Fortschritt der Übermittlung von Studienaufzeichnungen und zusammenfassenden Ergebnissen an ClinicalTrials.gov. Studienaufzeichnungen und gemeldete Ergebnisse werden von der National Library of Medicine (NLM) überprüft, um sicherzustellen, dass sie bestimmten Qualitätskontrollstandards entsprechen, bevor sie auf der öffentlichen Website veröffentlicht werden.
Haupttermine studieren
Studienbeginn (Tatsächlich)
8. Juni 2009
Primärer Abschluss (Tatsächlich)
31. Oktober 2012
Studienabschluss (Tatsächlich)
31. Oktober 2012
Studienanmeldedaten
Zuerst eingereicht
20. März 2009
Zuerst eingereicht, das die QC-Kriterien erfüllt hat
20. März 2009
Zuerst gepostet (Schätzen)
23. März 2009
Studienaufzeichnungsaktualisierungen
Letztes Update gepostet (Tatsächlich)
5. Dezember 2017
Letztes eingereichtes Update, das die QC-Kriterien erfüllt
30. Oktober 2017
Zuletzt verifiziert
1. Oktober 2017
Mehr Informationen
Begriffe im Zusammenhang mit dieser Studie
Schlüsselwörter
Zusätzliche relevante MeSH-Bedingungen
- Erkrankungen des Immunsystems
- Neubildungen nach histologischem Typ
- Neubildungen
- Lymphoproliferative Erkrankungen
- Lymphatische Erkrankungen
- Immunproliferative Erkrankungen
- Lymphom, Non-Hodgkin
- Lymphom
- Lymphom, B-Zell
- Physiologische Wirkungen von Arzneimitteln
- Antirheumatika
- Antineoplastische Mittel
- Immunologische Faktoren
- Antineoplastische Mittel, immunologische
- Antibiotika, antineoplastische
- Rituximab
- Inotuzumab Ozogamicin
Andere Studien-ID-Nummern
- 3129K5-2005
- B1931001 (Andere Kennung: Alias Study Number)
- 2008-007802-12 (EudraCT-Nummer)
Diese Informationen wurden ohne Änderungen direkt von der Website clinicaltrials.gov abgerufen. Wenn Sie Ihre Studiendaten ändern, entfernen oder aktualisieren möchten, wenden Sie sich bitte an register@clinicaltrials.gov. Sobald eine Änderung auf clinicaltrials.gov implementiert wird, wird diese automatisch auch auf unserer Website aktualisiert .